AKAP10

Across TCGA pan-cancer cohorts, AKAP10 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AKAP10 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher AKAP10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AKAP10 expression acts as an unfavorable survival marker.

LIHC, LUAD, and CESC are the cancer types where AKAP10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.076	0.553	.002	24	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	21	view →
CESC	DFS	Median	All	0.497	0.824	.005	12	view →
BLCA	DFS	Median	All	0.121	0.594	.009	9	view →
COAD	OS	Median	All	0.266	0.620	.028	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AKAP10–LIHC (DFS)

Open the LIHC breakdown →